A Potential Anti-Glioblastoma Compound LH20 Induces Apoptosis and Arrest of Human Glioblastoma Cells via CDK4/6...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Glioblastoma (GBM) is an aggressive brain tumor with frequent dysregulation of cell cycle control, particularly the CDK4/6-Rb pathway, found in ~80% of cases.
• Targeting aberrant cell signaling pathways is crucial for developing effective GBM therapies.

Purpose of the Study:

• To evaluate the anti-GBM efficacy of a novel pyrimidin-2-amine, LH20, in vitro.
• To investigate the mechanism of action of LH20 on GBM cell lines.

Main Methods:

• In vitro studies using U87MG and U251 GBM cell lines treated with varying concentrations of LH20.
• Assays included CCK8 for proliferation, wound healing for migration, Annexin V-FITC/PI for apoptosis, and cell cycle staining.
• Target prediction via SwissTargetPrediction and molecular docking, with Western blotting for mechanism confirmation.

Main Results:

• LH20 significantly inhibited GBM cell proliferation and migration at concentrations of 4-10 µM.
• The compound induced late-phase apoptosis, promoted necrosis, and caused G2/M cell cycle arrest.
• LH20 suppressed CDK4 and CDK6 activity by reducing Rb phosphorylation.

Conclusions:

• LH20 demonstrates potent anti-GBM effects in vitro.
• The compound's mechanism involves targeting the CDK4/6-Rb axis.
• LH20 represents a promising therapeutic candidate for glioblastoma treatment.